Over the past week, Vegzelma, a bevacizumab biosimilar, launched in the United States; 2 biologics license applications (BLAs) for biosimilars were accepted for review by the FDA; and China’s regulatory agency approved a denosumab biosimilar.
Over the past week, Vegzelma, a bevacizumab biosimilar, launched in the United States; 2 biologics license applications (BLAs) for biosimilars were accepted for review by the FDA; and China’s regulatory agency approved a denosumab biosimilar.
Vegzelma Launch
Celltrion Healthcare launched Vegzelma (bevacizumab-adcd), a biosimilar referencing Avastin (bevacizumab), for the treatment of several cancers, according to a Big Molecule Watch report.
The biosimilar was approved by the FDA in September 2022 for use alone or in combination with other agents in patients with metastatic colorectal cancer, non-squamous non-small cell lung cancer, glioblastoma, metastatic renal cell carcinoma, cervical cancer, and epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Vegzelma is also available in Canada, Japan, and the European Union. Celltrion said that the biosimilar has been added to the Medicare reimbursement list. Vegzelma is the fourth biosimilar for Avastin to launch on the US market, following Mvasi, Zirabev, and Alymsys, the last of which launched in October 2022. Vegzelma is the first Celltiron biosimilar to launch in the United States.
2 BLA Acceptances
The FDA accepted BLAs for 2 biosimilars: a ranibizumab product and a trastuzumab candidate.
The ranibizumab biosimilar was developed by Xbrane Biopharma and if approved, will be used to treat ophthalmic conditions, including age-related macular degeneration, macular edema, and diabetic retinopathy. The biosimilar references Lucentis (ranibizumab).
Xbrane said that it expects the FDA’s review process will take about 10 months, anticipating a decision on whether the product will be approved during the first half of 2024.
The trastuzumab biosimilar (HLX02) was developed by Shanghai Henlius Biotech and if approved, will be marketed by Accord BioPharma, according to Goodwin. Trastuzumab products reference Herceptin and are used to treat human epidermal growth factor receptor 2 (HER2)-positive breast cancer and HER2-overexpressing gastric or gastroesophageal junction adenocarcinoma.
The BLA included safety and efficacy data on HLX02 compared to the originator. HLX02 was also approved by the European Commission and China’s National Medical Products Administration (NMPA) in 2020. In 2021, Shanghai Henlius Biotech granted Accord Biopharma the exclusive rights for the development and commercialization of HLX02 in the U.S. and Canada.
China Approves Denosumab Biosimilar
Mabwell announced that China’s NMPA approved Mailishu, the second denosumab to receive regulatory approval in the world. The approval comes after the NMPA approved Luye Pharma Group’s Boyobei in November 2022.
Denosumab biosimilars reference Prolia/Xgeva and are used to treat and prevent bone loss and fractures associated with osteoporosis.
Panelists Call for Consistent Education, Support to Improve Patient Comfort With Biosimilars
May 15th 2024At the Festival of Biologics USA, panelists stressed the need for patient-centered communication and education to boost comfort with biosimilars, emphasizing consistent support from health care providers despite restrictive payer policies.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability
May 9th 2024As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Cencora Analysis Shows Differences in Payer Coverage Between G-CSF Biosimilars
May 2nd 2024Data from a Cencora study showed some misalignment in payer coverage of granulocyte colony-stimulating factor (G-CSF) biosimilars, highlighting that while filgrastim biosimilars are often favored over the originator, reference pegfilgrastim still dominates over its biosimilars.